Growth Hormone Declines With Age But Replacing It May Not Extend Life

Growth hormone is far more than a driver of childhood growth — in adults it regulates lean body mass, fat distribution, bone integrity, cardiovascular function, aerobic capacity, and cognition. When younger adults develop GH deficiency (AGHD), they experience measurable declines across all these domains, and GH replacement therapy effectively reverses them. This makes the natural, progressive decline in GH secretion that accompanies aging a compelling target for intervention.

With advancing age, the amplitude and frequency of GH pulses fall substantially, a phenomenon sometimes called the 'somatopause.' The resulting body composition shifts — increased visceral fat, reduced muscle and bone mass — closely parallel what is seen in AGHD, fueling the hypothesis that declining GH contributes meaningfully to age-related functional decline.

However, the picture is complicated by a striking paradox: animal models with congenital GH deficiency or GH resistance display dramatically extended lifespans, and humans with congenital GH deficiency appear to have reduced incidence of diabetes and certain cancers. This raises the possibility that the age-related drop in GH is not simply pathological but may carry protective trade-offs.

Multiple short-term clinical trials using exercise, direct GH administration, or GH secretagogues in older adults consistently improve body composition — reducing fat mass and increasing lean mass — but produce inconsistent benefits for physical performance, strength, or cognitive function. Side effects including edema, arthralgias, and hyperglycemia are well documented.

Critically, long-term data on hard outcomes — fracture risk, cancer incidence, cardiovascular events, and all-cause mortality — are absent. Until such data exist, routine GH supplementation in aging adults cannot be recommended, and the field remains in a state of cautious uncertainty.